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https://doi.org/10.1016/j.patter.2021.100270THE BIGGER PICTURE Methods that group genes into functional units to quantify pathway activities are
critical in the analysis of biological systems. Although many components of biological pathways have
been described in detail, these tend to be limited to well-studied genes. In contrast, the majority of
possible components remain unexplored. Here, we present a machine-learning tool for constructing
and predicting tissue-specific components of biological pathways from large biological datasets. Our al-
gorithm, ACSNI, can tackle incomplete pathway descriptions and enhance current pathway analysis
methods’ performance. We anticipate that, by dissecting the complex signals in biological data in a flex-
ible and context-specificmanner, ACSNI can facilitate the full characterization of physiological systems of
interest.
Development/Pre-production: Data science output has been
rolled out/validated across multiple domains/problemsSUMMARYDetermining the tissue- and disease-specific circuit of biological pathways remains a fundamental goal of
molecular biology. Many components of these biological pathways still remain unknown, hindering the full
and accurate characterization of biological processes of interest. Here we describe ACSNI, an algorithm
that combines prior knowledge of biological processes with a deep neural network to effectively decompose
gene expression profiles (GEPs) intomulti-variable pathway activities and identify unknown pathway compo-
nents. Experiments on public GEP data show that ACSNI predicts cogent components of mTOR, ATF2, and
HOTAIRM1 signaling that recapitulate regulatory information from genetic perturbation and transcription fac-
tor binding datasets. Our framework provides a fast and easy-to-use method to identify components of
signaling pathways as a tool for molecular mechanism discovery and to prioritize genes for designing future
targeted experiments (https://github.com/caanene1/ACSNI).INTRODUCTION
One feature common to all cells is the dynamic ability to coor-
dinate activities through many pathways that receive and pro-
cess signals from the environment and different cell regions.1
Hence, there has been a persistent interest in developing
pathway analysis approaches that group genes into functional
units and elucidate molecular mechanisms. Most approaches,
especially the techniques of pathway enrichment analysis and
network-basedmodeling, require accurate and comprehensive
pathway descriptions with annotated regulatory componentsThis is an open access article und(genes). However, the identities of the components within these
biological pathways and their regulatory interactions remain
either wholly unknown or partially understood.2 Even among
well-studied pathways, detailed annotations are scarce for
their disease- and tissue-specific components. This unmet
need argues for an expanded effort to identify these unknown
components.
Genetic, biochemical, and biophysical techniques such as
small interfering RNAs, small molecular inhibitors, immune pre-
cipitation, and gel filtration are common procedures for identi-
fying molecular functions and pathway components.3–5 The firstPatterns 2, 100270, June 11, 2021 ª 2021 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESS Descriptorstep toward designing these experiments is the identification of
candidate genes and their interacting partners. The large volume
of public gene expression profile (GEP) datasets, such as the tis-
sue RNA expression profiles in the Genotype-Tissue Expression
(GTEx)6 and The Cancer Genome Atlas (TCGA)7 projects, allow
for initial inference of pathway circuits and prediction of their un-
known components in a tissue- and disease-specific manner.
One popular approach applied to these large datasets involves
using pairwise correlation to represent the relationships between
genes.8 Visualizing these interactions as a network annotated
with external functional information such as STRING9 and Gen-
eMANIA10 reveals interactions of known pathway genes and
helps to discover additional related genes. However, these ap-
proaches make assumptions that do not account for the multi-
variate nature of gene regulation.2 For example, the transcription
of a single gene proceeds through the binding of transcription
factors on enhancer regions and the subsequent recruitment of
many co-activators and complexes that modify chromatin struc-
tures and promote the assembly of the basal transcriptional ma-
chinery.11 These complexities are not easily captured by simple
pairwise analysis between genes and the resultant binary inter-
action networks.
Another approach for identifying unknown components of
pathways involves first estimating a summarized pathway ac-
tivity from GEPs based on prior knowledge of the target
pathway using gene set enrichment analysis tools, such as
gene set variation analysis (GSVA), pathway-level analysis of
gene expression (PLAGE), single-sample gene set enrichment
analysis (ssGSEA), and the combined Z score (Z score),12–15
then correlating this compact value with the rest of the genes
to identify new components of the target pathway. However,
genes function in more than one pathway, and pathways
contain subprocesses,1 meaning that a single variable repre-
sentation of a pathway is unlikely to capture the target path-
way’s dynamics.
Here we provide software termed automatic context-specific
network inference (ACSNI), which leverages artificial intelligence
for the reconstruction of a biological pathway and aids the dis-
covery of pathway components and classification of the cross-
talk between pathways in specific tissues. The method draws
on the principle that cell signaling networks are organized into
several small, highly connected modules (herein called subpro-
cesses) that combine hierarchically into larger units to regulate
cellular functions.16 ACSNI combines the widely used and gen-
eral-purpose open-source TensorFlow-Keras library with a
probabilistic ensemble approach in a manner that adapts to
the particular needs of systems biology projects. For example,
it has functions that enable flexible adjustment for gene weights
within the pathway and linking pathway subprocesses to a
phenotype. We demonstrate the utility of ACSNI through three
different use cases, including the investigation of the mTOR
signaling pathway in kidney tumor and normal samples,
exploring the ATF2 network in the aorta, and identification of
HOXA transcript antisense RNA myeloid-specific 1 (HOTAIRM1)
target genes in kidney tissues. We find that ACSNI generates
validated and detailed, tissue-specific pathway circuitry and
components. The ACSNI predictions can guide researchers in
designing targeted experiments to study the molecular mecha-
nisms that underlie a biological state.2 Patterns 2, 100270, June 11, 2021RESULTS
Overview of the ACSNI method
ACSNI is a three-step method to infer tissue-specific compo-
nents (genes) of a pathway from tissue GEPs. It performs (1) un-
supervised derivation of pathway subprocesses, (2) estimation
of subprocess-gene interaction scores, and (3) inference of tis-
sue-specific components of the target pathway (Figure 1A; see
experimental procedures). ACSNI requires two input datasets:
a matrix of expression values, with genes listed in rows and tis-
sue samples listed in columns, and a file detailing gene set mem-
bership, representing prior knowledge of gene functions, such as
a gene set from the Pathway Interaction Database (PID)17 and
the MSigDB database.18 Depending on the research question,
ACSNI can take an additional file containing weights (as integer
values) for the genes in the second input. These data may repre-
sent transcription factor (TF) activity level or kinase function. In
the first step of ACSNI, we derivemultivariate pathway represen-
tation that defines the activity of the subprocesses in each sam-
ple (step i, Figure 1A). The step is performed with a deep neural
network (DNN) that decomposes the expression of the gene set
into pathway subprocesses under the assumption that genes
function in multiple subprocesses. In the second step, the sub-
process-gene interaction analysis is conducted on the whole
transcriptome using a linear model. We extract the model’s co-
efficient of determination as subprocess-gene interaction scores
(step ii, Figure 1A). We then classify the interaction scores to
identify the tissue-specific components of the pathway (step iii,
Figure 1A). The final output of ACSNI can be further mined
to identify biologically relevant pathway subprocesses and
components.
Performance evaluation
To assess the performance of ACSNI in reconstructing signaling
networks and their subprocesses, we utilized pseudo-simulated
and real expression datasets. It is natural to ask to what extent
the ACSNI predictions improve on current methods for inferring
the component of a pathway fromGEPs. Unfortunately, there are
no existing tools that provide such a granular view of pathway
subprocesses. Therefore, we focused our performance evalua-
tions on reconstruction of simulated signals and concordance
between two cohorts of similar samples.
ACSNI has robust signal reconstruction capabilities with
low type I error rate
In biological systems (i.e., tissues or organs), multiple signaling
pathways are executed concurrently with a certain level of
dispersion (i.e., a measure of pathway activity) across a group
of samples. ACSNI has been designed to extract differences in
pathway activity in a cohort of samples and detect unknown
components of the pathway. To assess how well the algorithm
achieves this aim, we first evaluated its ability to reconstruct a
known signal using pseudo-simulated GEPs under different
parameter settings (see experimental procedures). We simu-
lated randomGEPswith specific expected signals and noise sig-
nals, as described in datasets for simulation studies. Then, for
each GEP and the corresponding gene set, we tested the null hy-
pothesis for no difference in the proportion of the predicted
genes overlapping the expected or random signals. To examine
the effects of different ACSNI parameters, we ran the analysis
Figure 1. Overview of the ACSNI method and the robust signal reconstruction capabilities
(A) ACSNI reduces the expression of a gene set into a small number of subprocesses and derives corresponding gene interactions, while constraining the
optimization to reduce technical noise. Given two inputs, the expression matrix, and the binary gene set membership (pathway representation), the algorithm
starts by splitting the transcriptome into two parts: (1) expression of the genes in the gene set and (2) the expression of the rest of the transcriptome (transposed). It
then extracts the subprocess activities across samples (step i: W) from the expression profiles of the gene sets, interacts the subprocesses with the expression of
the rest of the transcriptome to extract subprocess-gene interaction scores (step ii: N), and classifies the scores to infer extended network of the pathway
represented by the gene set (step iii: P).
(B) Box plot of the percentage of the simulated signal recovered from the analysis of 50 gene sets against five GTEx tissue expression samples. Ex represents the
gene set signal, In the expected signal, and Rn the random signal.
(C) Box plot depicting the effect of random noise (log normal) on the percentage of gene set signal recovered from the analysis of 50 gene sets against five GTEx
tissue expression samples.
(D) Box plot showing the false discovery rates (FDR) from the analysis of 50 gene sets against five GTEx tissue expression samples (estimated as the number of
genes from the random signal divide the total number of predicted genes in B).
(E) Scatterplot of the relationship between FDR and size of the gene set.
(F) Box plot of Jaccard index of the similarity of predicted genes between two independent split or with one shuffled split (Null) across 50 curated gene sets.
(G) Box plot comparing the Jaccard index of predicted genes between two independent expression splits for randomly generated (R, n = 20) and curated (C,
n = 50) gene sets.
See also Figures S1 and S4.
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OPEN ACCESSDescriptorunder different parameter settings of classification threshold
(Alpha: 0.01, 0.05), latent space dimension (Percentage: 5, 10,
15, 20, 25, 30), feature selection threshold (Median absolute de-
viation: 1.2, 1.3, 3), and regularization (yes, no), repeating the
analysis 50 times with three ensemble models each to obtain
more stable results (see experimental procedures). Testing for
the overlap between the predictions and the expected signals re-
vealed that ACSNI recovered most of the expected signals
(average percentage of overlap = 98%, n = 250, Figure 1B)
compared with 3.5% random overlaps. The concordance of
ACSNI predictions with the expected signals is due to the
robustness of the DNN extraction core that dissects the gene
set expression patterns into subprocesses (see experimentalprocedures). As expected, ASCNI’s ability to recover the ex-
pected signal is negatively associated with the level of technical
noise (Figures 1C and S1A, see experimental procedures). These
results suggest that the quality of the prediction is dependent on
the level of technical noise (examples, errors due to RNA quality,
fragmentation, and amount of input) in the GEP measurements.
On average, more than 30% or 45% of the expected signal was
recoverable at 10% and 5% noise, respectively (Figures 1C and
S1A). Previous studies indicated that in RNA-sequencing (RNA-
seq) data sequenced to sufficient depth, the level of technical
noise is generally lower than 10%, while the rest of the expres-
sion variation is explained by biology and experimental condi-
tions.19,20 Thus, we believe that ACSNI retains its predictivePatterns 2, 100270, June 11, 2021 3
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OPEN ACCESS Descriptorpower when analyzing current real expression datasets across
various experiments and conditions (noise level <10%). Note
that latent space dimension, classification threshold, and feature
selection threshold had no effect on ACSNI’s ability to recover
expected signals.
To measure the type I error rate, we divided the number of
random predictions (false positives) by the total number of pre-
dictions (total positives) in the above simulation and assessed
the impact of different parameter settings. We observed a me-
dian false discovery rate (FDR) of 0.0045 (range, 0.003–0.005)
for default parameter settings across three feature selection
thresholds (Figure 1D; see experimental procedures). This
observation indicates that ACSNI has a low (<1%) rate of false
predictions. Applying a conservative feature selection
threshold (i.e., genes with median absolute deviation greater
than 3 across the cohort) before running ACSNI resulted in
tighter control of the FDR (median = 0.0038; range, 0–0.01) (Fig-
ure 1D). We next tested how key parameters, including classi-
fication threshold, dimension of the latent space, and gene set
size, affected the overall type I error rate of ACSNI. Relaxing the
classification threshold 0.01 and 0.05 significantly increased
the FDR (Wilcoxon test p = 3.4 3 1013, Figure S1B). Although
regularization did not affect the FDR (Figure S1C), increasing
the dimension of the latent space (a percentage of the gene
set size) significantly increased the FDR, but using 5% made
the FDR unstable (Figure S1E). We found a positive correlation
(Pearson’s r = 0.93) between gene set size and FDR (Figure 1E).
These associations are expected because larger gene sets and
genes with a low variability are more likely to result in aberrant
predictions. However, even in the case of a larger gene set
(>80, Figure 1E) we expect the FDR to be less than 1% (see
experimental procedures).
We then tested whether the approach was a robust predic-
tor of pathway components across different cohorts of similar
samples. To this end, we randomly sampled two non-overlap-
ping groups of 290 samples from the 580 samples of the GTEx
healthy adult lung dataset to generate a training cohort and a
test cohort. We also randomly shuffled the test cohort to
generate a null model (see experimental procedures). Next,
we individually analyzed these three cohorts (training, test,
and null model cohorts) with ACSNI using 50 gene sets from
the MSigDB database18 and quantified the similarity of the in-
ferred circuitry between the training cohort and the test cohort
compared with the similarity between the training cohort and
the null model. Predicted circuitry from the training cohort
was significantly more similar to the test cohort compared
with the null model (t test, p = 4.6 3 107, Figure 1F). We
repeated the above analysis using 20 randomly assigned
gene sets and observed no difference between the real co-
horts and the null model, as the random inputs lacked under-
lying regulatory mechanisms. Consistently, manually curated
gene sets show a significantly higher similarity between
training cohort and test cohort compared with the simulated
gene sets (t test, p = 1.3 3 103, Figure 1G). The level of sim-
ilarity between two expression cohorts is independent of the
type of pathway and the size of the gene set (Figure S2A).
Combined, these results indicate that ACSNI predictions are
reproducible, with datasets of similar biological and regulatory
information.4 Patterns 2, 100270, June 11, 2021ACSNI identified the mTOR crosstalk with KLF6 and
EPAS1 signals in ccRCC
To evaluate the performance of ACSNI on real data, we simu-
lated a condition whereby known context-dependent signaling
crosstalk was expected. Specifically, a recurrent event in
clear-cell renal cell carcinoma (ccRCC) is the hyperactivation
of the mTOR signaling that promotes oncogenic metabolic
programs.21,22 The crosstalk between mTOR, KLF6, and
EPAS1 (HIF2A) signaling contributes to this metabolic program
that drives ccRCC progression. KLF6 is a zinc finger DNA-
binding TF activator of mTOR signaling that co-regulates lipid
metabolism, cell growth, and cell fate in ccRCC.23 mTOR reg-
ulates transcription of EPAS1,24 which in turn activates a
superenhancer that supports KLF6 expression,23 creating a
complex feedback loop between mTOR, KLF6 and EPAS1
signaling.
Consistent with the above, we hypothesized that mTOR
signaling network derived from GEPs in ccRCC patients could
enrich for both KLF6 and EPAS1 signals. To test this hypothesis,
we collected data of 73 ccRCC samples with matched normal
adjacent tissues from the TCGA ccRCC project (KIRC, n =
146). We applied ACSNI to the RNA-seq data using a publicly
available curated mTOR signaling gene set from the PID
(n = 67).17 We derived ten subprocesses of mTOR signaling
that were strongly associated with 1,166 genes (Figure S2B).
We next evaluated the biological processes associated with
mTOR signaling in this context. Using gene ontology analysis,
we found a strong enrichment of catabolic processes and amino
acid biosynthesis ontologies (Figure 2A), consistent with the role
of mTOR signaling in cell metabolisms.25 To assess whether the
ACSNI-predicted mTOR signaling captured KLF and EPAS1
signal, we first defined KLF6 and EPAS1 signals as differentially
expressed (DE) genes from publicly available gene perturbation
datasets: (1) KLF6 knockout (KLF6-KO, DE = 1,378 genes) and
(2) EPAS1 knockout (EPAS1-KO, DE = 303 genes) in the 786
ccRCC cell line.23,26 The inferred network had significant over-
representation of KLF6 (1.47-fold, chi-squared p = 1.763 3
1012, Figure 2B) and EPAS1 (2.07-fold, chi-squared p =
1.009 3 103, Figure 2B) signals compared with background
enrichment (i.e., all genes in the expression dataset). Inspecting
the ACSNI subprocesses and their associated genes, we found
unique associations with KLF6 and EPAS1 signals (Figure 2C).
Subprocesses, w3, w7, and w9 were exclusive to KLF6 signal
and w0 was exclusive to EPAS1, while w4, w5, and w2 captured
both signals but have relatively more enrichment of EPAS1 signal
(Figure 2C). Three subprocesses (w8, w6, and w1) appear to
capture signals unrelated to KLF6 and EPAS1. These observa-
tions demonstrate that ACSNI models the complexities of a
signaling network as represented by an experimentally curated
gene set.
We next investigated the specificity of ACSNI by comparing
our predictions with KLF6 and EPAS1 signals from non-ccRCC
cells lines as non-specific controls (including endothelial cells
[human umbilical vein endothelial cells—HUVECs] and primary
peripheral blood mononuclear cells [PB-CD34+]). We found an
insignificant over-representation for DE genes (n = 119) derived
from EPAS1-KO in HUVECs (0.91-fold, chi-squared p =
7.4823 101, Figure S2C), underlining the advantage of detect-








Figure 2. ACSNI identified pathway components and signaling crosstalk
(A and B) (A) Bar plot of the top 25 significantly enriched biological processes associated with the predicted 1,166 genes mTOR signaling components. Bars are
ordered from top to bottom according to FDR values. (B) Association of ACSNI-predicted mTOR signaling genes (TCGA) with DE genes in KLF6 and EPAS1
knockout in ccRCC cells, divided into datasets (KLF6: 786 = GEO: GSE115763, EPAS1: 786 = GEO: GSE115389). Chi-squared tests (Chisq, p) and ACSNI-
predicted (P) and background (B) are indicated on top of the panel. DE and nDE represent differentially or non-differentially expressed genes at adjusted p value of
<0.05, respectively.
(C) Bar plot comparing enrichment of DE genes from EPAS1-KO (red) and KLF6-KO (blue) across the different ACSNI-derived subprocesses of mTOR
signaling (TCGA).
(D) (Left) Heatmap of the coefficient of determination (R2) of the linear model of ACSNI-derived mTOR activity and disease status (cancer or normal adjacent
tissues) across ten subprocesses. The higher the R2, the more significantly related is the subprocess to disease status. (Right) Expression of mTOR subprocess
w8-associated genes in ccRCC cell lines following the inhibition of mTOR pathway with everolimus (Eve) compared with vehicle control (Cont) (GEO:
GSE106819). Within the plot differential expressions at FDR < 0.05 (DE) are indicated (upregulated, red; downregulated, blue; unchanged, white).
(E) Ranked dot plot of the ratio of transcription factor (TF) ChIP density at the promoter regions (± 1 kb from TSS) of the ACSNI-predicted ATF2 signaling genes
relative to background genes in artery aorta. DNA-binding domains are highlighted in red.
(F) Bar plot comparing ratio of TF ChIP density at the promoter regions (±1 kb from TSS) of the ACSNI-predicted ATF2 signaling genes across the different ACSNI-
derived subprocesses from artery aorta.
(G) Gene ontology analysis of biological processes associated with predicted HOTAIRM1 genes and DE genes in HOTAIRM1.
See also Figures S2–S4.
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OPEN ACCESSDescriptorsignificant enrichment for DE genes (n = 8,487) derived from
KLF6-KO in PB-CD34+ (1.2-fold, chi-squared p = 1.56 3 109,
Figure S2C), suggesting that the mTOR-KLF6 axis may be appli-
cable to multiple tissues. However, these data had an unusually
high level of DE genes (60%, 8,487 out of 14,260), which may be
related to the fact that the experiment was performed in primarycells. To further validate our predictions, we applied ACSNI to an
independent dataset of GEPs of tumor and normal adjacent tis-
sues from ccRCCpatients (n = 22, GEO: GSE102101)27 using the
same mTOR gene set described above. We evaluated the
robustness of the initial predictions against the new predictions
using a randomization test (see experimental procedures). WePatterns 2, 100270, June 11, 2021 5
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OPEN ACCESS Descriptorfound that 19% (98/516, only genes measured in both datasets)
of the predicted genes among these data overlap with the KIRC
predictions (Figure S3A, left panel), which is significantly higher
than would be expected by random chance (empirical p = 0.0,
95% confidence interval 23–44) (Figure S3A, right panel). There
was no enrichment of KLF6 and EPAS1 signals in the corre-
sponding null models (Figure S3C; see experimental proced-
ures), confirming that our predictions and validation were robust.
As an additional layer of performance evaluation, we next
compared ACSNI global predictions against predictions based
on pathway activities estimated from GSVA, PLAGE, ssGSEA,
and Z score (see experimental procedures).12–15 ACSNI recov-
ered the strongest enrichment of KLF6 (1.91 mean fold enrich-
ment) and EPAS1 (2.17 mean fold enrichment) signaling cross-
talk with mTOR pathway compared with mean fold enrichment
of 1.71 (KLF6) and 1.44 (EPAS1), 1.17 (KLF6) and 1.16
(EPAS1), 0.77 (KLF6) and 0.55 (EPAS1), and 0.94 (KLF6) and
0.89 (EPAS1) mean fold enrichment for GSVA, PLAGE, ssGSEA,
and Z score, respectively (Figure S3B). These results indicate
that our framework can provide additional context-specific infor-
mation to aid the interpretation of GEPs.
ACSNI-derived mTOR subprocesses predict clinical
traits in ccRCC
The identification of biologically or clinically essential pathway
subprocesses is a crucial aim of many signaling network ana-
lyses. ACSNI provides additional functions to map the derived
network to a target biological or clinical variables. To demon-
strate the utility of this function, we analyzed the distribution of
the mTOR subprocesses across the tumor and normal adja-
cent tissue from the TCGA datasets (variable: disease status).
We found that three subprocesses (w8, w6, and w3) were
strongly associated with the disease status (Figure 2D, left
panel). Interestingly, two of these (w8 and w6) were not asso-
ciated with KLF6 nor EPAS1 signal (Figure 2C), suggesting that
they may harbor new insight into mTOR-dependent mecha-
nisms of ccRCC development. To investigate this hypothesis,
we first sought to confirm the regulation of the w8-associated
genes (the top disease-associated subprocesses) by mTOR.
To this end, we analyzed published GEP data (GEO:
GSE106819)28 which utilized the mTOR inhibitor, everolimus,
to characterize the differential gene expression changes that
occur due to mTOR signaling in ccRCC cell lines. Among the
13 genes associated with w8 in ACSNI predictions, 77%
(10/13 genes) were significantly altered by mTOR inhibition
(Figure 2D, right panel), confirming that w8 is within the
mTOR signaling network. Of the total ten w8 genes altered
by everolimus, 70% (GINS2, CCDC130, PRR22, CYP4F2,
PGLS, LY9, and BCHE) have been identified as essential
ccRCC genes in a CRISPR genome-wide loss-of-function
screen29 (Figure S2D). These observations suggest that these
genes may co-regulate oncogenic programs in ccRCC
through mTOR signaling.
ACSNI identified ATF2-dependent targets of bZIP
transcription factors in artery aorta
Identification of functional TFs and their regulatory output is
essential for understanding gene-regulatory mechanisms in
many cellular processes.30 ACSNI can provide information about
the context-specific regulatory output of TFs in a gene set. As an
example, here we focus on cAMP response element-binding6 Patterns 2, 100270, June 11, 2021proteins (CREBs) and CREB-like TFs that dominate ATF2
signaling (10 out of 13 TFs). These genes represent a large family
of TFs that bind cAMP-responsive elements and share a basic
leucine zipper DNA-binding (bZIP) domain. Complex dimeriza-
tion between these TFs increases the selectivity of bZIP-DNA in-
teractions and binding diversity, allowing them to regulate multi-
ple vascular functions.31 We hypothesized that ATF2 network
circuitry derived fromGEPs of artery aortas should enrich targets
of the bZIP TFs.
We analyzed the ATF2 TF signaling gene set from the PID (n =
31)17 in artery aorta (n = 433) GEPs from the GTEx project.6 We
produced four subprocesses associated with 683 genes, repre-
senting the context-specific activity of bZIP TFs (Figure S2E).
Using an independent dataset of human TF chromatin immuno-
precipitation (ChIP)-sequencing measurements from primary
human aortic endothelial cell lines from chip-atlas (https://chip-
atlas.org), we evaluated the enrichment of the available eight
TFs (bZIP = 4, others = 4) at the promoter regions (±1 kb from
transcription start site [TSS]) of the predicted genes compared
with the background (enrichment = mean peak density of pre-
dicted genes/mean peak density of background genes).
ACSNI-predicted genes were strongly enriched for bZIP tran-
scription factor binding (ratio > 1) but depleted of other families
of TFs (ratio < 1) (Figure 2E). We observed no significant enrich-
ment of bZIP TF for predictions from a null model derived by
random shuffling of the expression matrix (Figure S3E; see
experimental procedures), confirming that our predictions and
validation were robust. On average, the predicted genes had
significantly higher binding of JUNB (Wilcoxon test, p =
2.083 3 109), CEBPD (p = 1.278 3 104), NFE2L2 (p =
1.168 3 103), and JUN (p = 1.041 3 102) compared with the
background genes. Conversely, we observed significantly lower
binding for EP300 (p = 7.5823 1032), RELA (p = 7.1323 1010),
ERG (p = 1.841 3 105), and IRF1 (p = 3.148 3 102) compared
with the background genes. Interrogating the ACSNI-derived
subprocesses of ATF2 signal and their associated genes re-
vealed unique associations with different bZIP dimerization pat-
terns (Figure 2F). Specifically, w0, w1, and w3 were exclusive to
CEBPD, JUN, and JUNB, respectively. While w2 enriched for
NFE2L2, JUNB, and CEBPD, with higher JUNB, w4 enriched
for all four bZIP TFs measured in these data (Figure 2F). These
observations suggest that ACSNI can segregate different TF sig-
nals into specific subprocesses of the W matrix by leveraging
external knowledge to anchor RNA expression to TF activities
underlying complex cell processes.
To benchmark our results, we analyzed the enrichment of
these TF signals on the genes predicted based on pathway ac-
tivities estimated by GSVA, PLAGE, ssGSEA, and Z score (see
experimental procedures). Predictions derived from pathway
activity scores generated from these methods showed high
enrichment rank for non-bZIP TFs (EP300, RELA, ERG, and
IRF1) and largely low in signal for the bZIP TFs (JUNB, CEBPD,
NFE2L2, and JUN) (Figure S3D). Compared with ACSNI, the
alternative approach based on these methods showed non-
significant enrichment for all the TFs regardless of the DNA-
binding domain. These results demonstrate how ACSNI
predicts context-specific TF targets and enables discovery of
pathway-level regulatory mechanism and interpretation of
expression profiles.
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OPEN ACCESSDescriptorACSNI annotates the function of HOTAIRM1 using de
novo derivation of gene sets
ACSNI also provides tools to help annotate genes with unknown
functions, such as long non-coding RNAs (lncRNAs). To demon-
strate this utility, we focused on the annotation of the lncRNA
HOTAIRM1. Specifically, HOTAIRM1 is a natural antisense tran-
script of the HOXA1 gene that plays roles in kidney differentiation
and regulation of HIF1-dependent angiogenic pathways.32 We
hypothesized that the ACSNI-inferred network of HOTAIRM1
could reveal its kidney-specific functions.
To this end, we leveraged the GTEx project of GEPs in
normal kidney tissues and investigated the network of HO-
TAIRM1. Because this case deals with a single gene, we uti-
lized the ACSNI-derive module to first generate a de novo
gene set (n = 50) before running two iterations of ACSNI (see
experimental procedures). We identified 729 genes that were
strongly associated with the network of HOTAIRM1 in kidney.
To evaluate the functional relevance of the predictions, we
initially analyzed published data (GEO: GSE136604)32 that uti-
lized knockdown of HOTAIRM1 to characterize the differential
gene expression changes that occur due to its activity in hu-
man kidney cells (HOTAIRM1-KO). We then cross-referenced
the ACSNI-predicted genes to establish whether the predic-
tions enriched the lncRNA activity compared with random
backgrounds. For the genes measured in both datasets (n =
390), the DE genes identified in the HOTAIRM1-KO data (n =
85) showed a significant overlap with ACSNI-predicted HO-
TAIRM1 genes (12/85, 14.11%; empirical p = 8 3 105, only
genes measured in both datasets, Figure S3F). To assess
the biological processes regulated by HOTAIRM1 in this
context, we performed gene ontology analysis on the
ACSNI-predicted genes compared with the ontologies associ-
ated with the DE genes in the HOTAIRM1-KO. The results
showed strong concordance in the enrichment of ontologies
involved in vascular functions and angiogenesis (Figure 2G).
We also observed an enrichment of metabolic processes, sug-
gesting that HOTAIRM1 may play a role in cell metabolism in
the kidney (Figure 2G).
We next evaluated the robustness of the predictions by
comparing the enrichment with predictions from a null model
derived by random shuffling of the expression matrix. We
found no significant enrichment of genes differentially ex-
pressed in the HOTAIRM1-KO data (Figure S2F), confirming
that our predictions and validation using the non-shuffled
data did not occur by chance. Correlation and differential
gene expression analysis are the two commonly used
methods for identifying functional lncRNA targets from
GEPs. Thus, we compared ACSNI predictions with direct cor-
relation or differential expression test for pairwise gene inter-
action analysis on the same input expression data above
(see experimental procedures). ACSNI predictions recovered
the most overlap with HOTAIRM1 signal (14.11%) compared
with zero overlap and 1.19% overlap for differential expres-
sion-based and correlation approaches, respectively (Fig-
ure S3G). Consistently, genes predicted by both methods
were not enriched in ontologies involved in vascular functions
and angiogenesis. These results suggest that ACSNI can
leverage the annotation of protein coding genes to provide
functional annotation for poorly annotated genes.DISCUSSION
Our knowledge of biological pathways and their components is far
from complete. This situation limits the accuracy of the current
pathway and network analysis methods that depend on accurate
and detailed pathway annotations. ACSNI enables the identifica-
tion of tissue-specific components of biological pathways from
gene expression data. This approach overcomes the limitations
of using composite scores or representative values, which are un-
able to fully capture the process or handle the inherent variability in
GEPs within a gene set. By contrast, ACSNI can capture pathway
modules while reducing the impact of technical noise. This capa-
bility was demonstrated in our identification and validation of
mTORsignaling crosstalkwithKLF6 andEPAS1 in ccRCC.ACSNI
can also reveal the context-specific output of TFs in a gene set
and identify lncRNA network in expression data. This utility is
especially vital in mechanistic studies where the target is
context-specific gene regulation. By using prior knowledge and
interrogating associated expression variability in GEPs, ACSNI
can identify biological network within a specific tissue and has
the flexibility to apply weights to the prior information.
Using an autoencoder the core of ACSNI decomposes GEP
intomultiple pathway subprocesses, which are then used to infer
unknown pathway components. Other dimension-reduction
methods, including principal component analysis (PCA) and
non-negative matrix factorization (NMF), could also theoretically
be used to estimate pathway subprocesses from GEPs. The key
limitation of these methods is that the mapping from the gene
expression space to the low-dimensional representation is
restricted to be linear.33 However, an accurate model of the ac-
tivity of biological pathways encoded in GEPs requires a mix of
both linear and non-linear transformations. Our comparative
analysis showed that replacing the autoencoder in step 1 with
PCA or NMF resulted in no enrichment of the expected signal
(Figure S4C) or extraction of non-specific signals (Figure S4D).
Therefore, the autoencoder approach used for step 1 is more
capable of extracting biologically meaningful results compared
with simple linear reductions (Figures S4C and S4D), consistent
with previous studies.34
Onepotential limitation is a lackof prior knowledge in the formof
a gene set; this can be partially remedied by ACSNI-derive, which
enables de novo generation of gene sets as demonstrated in the
annotation of HOTAIRM1 functions. In addition to the availability
of prior information, ambiguous annotations, sample size, gene
set size, and expression variance can all affect the performance
of ACSNI. Currently, ACSNI depends on RNA expression across
a cohort of samples to infer pathway circuitry and will miss post-
translation interactions, since RNA levels may not correlate with
protein output.35 Despite these limitations, ACSNI supplements
the existingmethods to identify pathway components and extract
biologicalmeaning from transcriptomicdata andcanbeapplied to
study processes that have little prior knowledge.
Independent validation of the inferred network is an essential
step in the discovery of pathway components and their
functional interactions. Ideally, such analysis should involve in-
dependent genetic perturbation data, reporter assays, or DNA
occupancy analyses as demonstrated in our use cases. Howev-
er, genetic perturbation or DNA occupancy data may not always
be available. Literature mining can be an alternative approach,Patterns 2, 100270, June 11, 2021 7
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OPEN ACCESS Descriptorbut the results may be confounded by publication bias. Our re-
sults show that this framework effectively infers biological net-
works from GEP datasets and enables the discovery of novel
functional interactions. Analysis of publicly available GEP data
using ACSNI will lead to new insights into the molecular basis
of a phenotype and its deregulation in disease.
It is well established that signaling pathways are coordinated
by complex interdependences between chromatin structure,
DNAmodifications, RNA abundance andmodifications, and pro-
tein abundance andmodifications.While ACSNI includes the op-
tion to account for one additional piece of regulatory information
as an integer variable, this is unlikely to model the complete in-
terdependences. We plan to further develop the ACSNI software
by expanding the utilization of other genomic information.
Conclusion
ACSNI offers the cell and molecular biologist a flexible approach
to infer potential pathway components that can be used to guide
functional analysis in a target signaling network. The ACSNI pack-
age provides command-line functions (ACSNI-run and ACSNI-
derive) for predicting the components of a signaling pathway
from GEPs using prior knowledge. It also provides a function
(ACSNI-get) to describe the correlation between the derived
pathway subprocesses and biological traits. The ACSNI packageREAGENT OR RESOURCE SOURCE
Deposited data
TCGA ccRCC dataset Cancer Genome Atlas
Research Network, 201
GTEx expression datasets Lonsdale et al., 20136
Validation ccRCC dataset Yao et al., 201727
KFL6-ko data in ccRCC cells Syafruddin et al., 201923
EPAS1-ko data in ccRCC cells Zou et al., 201936
KFL6-ko data in blood cells Adelman et al., 201926
EPAS1-ko data in endothelial cells Yoo et al., 201537
mTOR-inhibition data in ccRCC cells Kornakiewicz et al., 201
HOTAIRM1-ko data in kidney cells Hamilton et al., 202032
TF ChIP-Seq datasets Oki et al., 201838
Cancer-cell dependency data Tsherniak et al., 201729
Pathway interaction gene sets Schaefer et al., 200917
MSigDB v7.2 Liberzon et al., 201118
Software and algorithms
ASCNI This paper
Trimmomatic v0.39 Bolger et al., 201439
HISAT2 v2.1.0 Pertea et al., 201640
HTSeq v0.11.1 Anders et al., 201541
Python v3.8.6 PSF
R v4.0.3 CRAN
8 Patterns 2, 100270, June 11, 2021includes a function (ACSNI-split) to process GEPs for bootstrap
analysis. Users can install the Python package and its depen-




Further information and requests for the implementation and troubleshooting
the ACSNI software should be directed to and will be fulfilled by the lead con-
tact, Chinedu Anthony Anene (a.anene@qmul.ac.uk).
Materials availability
This study did not generate new materials.
Data and code availability
This paper analyzes existing, publicly available data. The ACSNI Python pack-
age is publicly available at GitHub, https://github.com/caanene1/ACSNI, and
can be installed through the pip python installer. The code used to process and
generate the figures reported in this paper is available at GitHub, https://
github.com/caanene1/ACSNI. Any additional information required to repro-
duce this work is available on the package documentation at GitHub,
https://github.com/caanene1/ACSNI, and from the lead contact.
Publicly available datasets and software.
Method details
ACSNI algorithm
We introduce ACSNI, an algorithm to infer the components of a biological






























OPEN ACCESSDescriptorpathway (Figure 1A). Let P denote the activity of the target pathway in a given
biological sample andK (minimumof 4 genes) a curated set of genes associated
with P based on current knowledge of their biological functions (gene set).42 We
assume that P is organized into several small, highly connected subprocesses
(Si–n) that combine hierarchically into larger units.




Si ; (Equation 1.1)
where Si is the contribution of the i
th subprocess to the pathway P and n is the
total number of subprocesses.
While the hierarchical model is a faithful description of cell signaling path-
ways, a practical issue is that the number of subprocesses (n) is unknown a pri-
ori. Our best estimate of n is the current knowledge of the target biological
pathway (P), as specified by the gene set K. To address this issue, we let n
depend on the cardinality of the gene set |K|, defined as a percentage of |K|
and estimated using a recent algorithm explicitly developed for autoencoders
(described below).43 Alternatively, n can be specified by the user based on
their knowledge of the target pathway.
For each k˛K, wehave anestimateof its expression level acrossa cohort ofN
samples indexed by j. We let Vk be the scaled expression vector for gene k and
Vkj is the expression of k in the j
th sample; determined by RNA-seq. Since genes
act inmultiple pathways and subprocesses,44 it is the additive change in expres-
sion within subprocesses that leads to the difference in pathway activity. Thus,




kjwj +bj ; (Equation 1.2a)
where bj is a constant error term for the j
th sample, wj is the influence of the j
th
gene on the subprocess Si and kj is the expression value of k gene in the j
th
sample. To account for additional prior knowledge, we include an optional




kjwj,rj + bj ; (Equation 1.2b)
where r denotes the gene-level weights of the new information, such as TF
activity, protein family, or kinase group.Unsupervised derivation of pathway subprocesses (Sn)
ACSNI starts from the RNA expression values for the K genes and estimates
the activities of the subprocesses across the samples. To this end, we imple-
ment a DNN for estimating Snj through a pair of encoder and decoder layers
(autoencoder):
Vk = d½fðVkÞ; (Equation 1.3)
where f (encoder) is a function of the expression to the pathway (P), d (decoder)
is a function of the pathway to the expression, and Vk is the reconstructed
version of the expression vector. We train the network to find a solution to
the optimization problem:
minjd; f
Vk d½fðVkÞ; (Equation 1.4)
where ||. || is the l1 and l2 norms that disallow the identity map and forces the
model to learn a sparse representation. The variation across the samples in-
forms the compression and reconstruction of the expressions for all k ˛ K.
We restrict feature selection to the removal of uninformative genes that have
a median absolute deviation below a threshold (user-defined value >1, default
2.5). Figure S4A illustrates the mapping between the biological system, math-
ematical model and DNN layers.
To determine the optimal number of dimensions (i.e., the unknown n subpro-
cesses in Equation 1.1), we implement a recent algorithm explicitly developed
for estimating latent space dimension in autoencoders.43 Specifically, we
determine the optimal latent space for each gene set expression profile by
an iterative process, including:1. Run the autoencoder above using 50% of the gene set’s cardinality
(50 3 |K|/100) and extract the latent structure.
2. Apply the Bahadur and Paffenroth algorithm to this latent structure to
estimate the optimal dimension.
3. Fix and run ACSNI with the estimated dimension.
In step 1, we initiated the search at 50% of the gene set based on simulation
analysis that showed that although increasing the dimension of the latent
space does not affect the ability to recover the expected signal (Figure S1D),
it comes at the cost of increasing the FDRs (Figure S1E), which we want to
minimize. Latent dimension below 50% of the gene set size appear to achieve
the optimal balance between FDR and recovery of expected signals. Since our
ultimate aim is to prioritize biological components without inflating false dis-
covery, a small dimension is preferred.
Other dimension-reduction methods, including PCA and NMF, have been
applied to gene expression datasets and could theoretically be used to esti-
mate pathway subprocesses (Snj). Therefore, we also implement PCA and
NMF, two linear dimension-reduction methods, into the ACSNI software, al-
lowing users to cross-compare the results.
Estimation of subprocess-gene interaction scores
The neural network above minimizes the error between the input expres-
sion vector Vk and the reconstructed version (Vk ). However, it is, not the
values of Vk that are of interest to us but rather the subprocesses in
each sample. Thus, after training the autoencoder, we extract the learned
weights (W matrix) of the first hidden layer, which represents the reduction
of the gene set expression profiles to latent structures. W has a dimension
of m 3 n (m = the total number of samples and n = the number of estimated
subprocesses) and is the activity of the subprocesses defined in Equa-
tion 1.2a or 1.2b.
For the rest of genes in the transcriptome, the strength of the linear relation-
ship between their expression and the vector of W above corresponds to per-
gene interaction between individual latent vectors and the gene.Wemodel this
interaction as
a = bSi + ε ; ,(Equation 1.5)
where a is the expression profile of a gene in the rest of the transcriptome, b is
the slope, Si is the activity of i
th subprocess, and ε is the intercept, estimated
automatically.
Next, for each run of Equation 1.5, we extract the R2 (here called interaction
score e); this can be interpreted as the coefficient of determination for the pro-
portion of the variance in that gene’s expression across the samples that is
predictable from each vector of the W matrix, defined as
e = 1
P ðaj  baj Þ2P ðaj  aÞ2 ; (Equation 1.6)
where e is the interaction score, aj is the expression value for sample j, baj is the
predicted expression value for sample j and a is the mean expression value.
The Equations 1.5 and 1.6 were estimated using the Linear model function
implemented in the sklearn Python package, using default parameters. We
define the matrix of interactions scores (e) with genes in the row and subpro-
cesses in the column as the (Nmatrix), which is used for prediction of unknown
pathway components below.
Further, we extract the learned weights of the second hidden layer (Code),
which represents the reduction of the subprocesses to the pathway. Code
has a dimension of m 3 n (m is the number of estimated subprocesses and
n is the number of estimated higher pathway units) and is the activity of the
pathway defined in Equation 1.1. These data can be used for diagnostics
and dimension plots.
Inference of tissue-specific components of the target pathway
Having estimated the multiple interactions between the subprocesses of the
target pathway and genes in the rest of the transcriptome, we classify each
subprocess independently and combine the predictions into a network. This
process intuitively captures the signal contained in the gene set and thus rep-
resents a robust measure of the context-specific circuitry of the target
pathway. Let en be the scores for the interaction between the i
th subprocess
and the genes in the rest of the transcriptome (bound 0–1). e has a betaPatterns 2, 100270, June 11, 2021 9
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where mis the mean interaction across the rest of the transcriptome with vari-
ance s2.
For a future experiment, it is the regularized incomplete beta function Ij(a; b)
that defines the impact of a subprocess on the j gene and in turn the pathway
network. However, we find a cumulative distribution function to be an imprac-
tical network measure and therefore discretize it by defining the interactions to
be Ij(a; b) < 0.01 (P matrix). The cutoff can be interpreted as the probability
threshold to reject the null hypothesis that such an extreme value is expected
less than 1% of the time. Simulation analysis showed that the 0.01 cutoff re-
duces the FDR without affecting the ability to recover the expected signal
compared with the traditional 0.05 for rejecting a null hypothesis (Figure S1B).
The user can also adjust the cutoff depending on their aims.
Next, for each subprocess (Equation 1.2a or 1.2b), we extract the genes that
reach the above threshold as the individual subprocess network. Finally, we
represent our global network for the pathway (Equation 1.1) as the union of
all the genes predicted across the subprocesses, thus a global network across
all subprocesses. Since the neural network optimization process is stochastic,
we implement an ensemble learning and combine predictions using summary
statistics. Here, we count the number of times a gene is predicted across the
ensemble and retain genes predicted in at least twomodels. We suggest using
at least an ensemble of threemodels to increase the stability of the predictions.
Mapping subprocess activity to external variable
Here, we define a subprocess significance measure as a function SS that as-
signs a non-negative value (0–1) to each subprocess; the higher is SSw, the
more biologically significant is subprocess w for the given variable. We derive
SS using logistic regression for categorical variable or simple linear regression
for numerical variables, implemented as the ACSNI-get module (see code at
https://github.com/caanene1/ACSNI).
Architecture and hyperparameters
The neural network used in ACSNI consists of two fully connected layers and a
mirror image of this neural network as a decoder (Figure S4A shows the map
between the biology, equations, and the network layers). We used x neurons in
the first layer, and (x/2) neurons in the second layer of the network. x is
automatically determined, as described in estimation of subprocess-gene
interaction scores, or is user defined based on prior knowledge. During the
subprocess-gene interaction analysis, we extracted the learned weights of
the first layer (autoencoder) or the loading of the linear dimension-reduction
controls (PCA and NMF controls) and used these to predict gene expression
values. We used RMSprop optimizer with learning rate of 13 103 for training.
Activities of the neurons were normalized using layer normalization that calcu-
lates the normalization statistics for all units in the same layer. The RELU func-
tion, defined as RELU(x) = max(0, x), was used as a non-linear activation in the
two layers. In the mirror image, the Sigmoid function, defined as Sigmoid(x) =
1/1 + ex, was used as the activation function. We train the model for 3,000
epochs and configure the checkpoint to save at the end of every epoch, if it
is the best model seen (i.e., the lowest mean squared error in the ACSNI objec-
tive function [1.4]). Regularizers l1 and l2 in the ACSNI objective function were
set to 13 1016 and 13 109, respectively. ACSNI is implemented in Python 3
and relies on the tensorflow, sklearn, numpy, and pandas packages.
Requirements
The validity of the approach is related to the quality of the starting gene set; the
higher the quality of the sources that link the genes in a pathway, the better the
subprocess estimates. The changeable and partially arbitrary nature of gene
annotations should be considered before treating gene sets as units of biolog-
ical processes. It is a further requirement that the sample cohort should mini-
mally contain 50 samples and come from the same type of tissue.
De novo generation of gene sets (ACSNI-derive)
The requirement for a pre-annotated gene set is a challenge because many
biological processes remain completely unknown. For example, few gene10 Patterns 2, 100270, June 11, 2021sets are available for the pathways of non-coding RNAs. To address this prob-
lem, we develop the ACSNI-derive tool for de novo creation of a gene set given
a single gene. First, the expression of the gene of interest is correlated with the
expression of other genes (this can also be set for a specific biotype only, for
example, lncRNA, microRNAs, or protein coding). The topmost correlated tar-
gets are then selected to construct a search space and negative controls (top
50 with r > 0.6 and r < 0.6). We search this space using multiple iterations of
ACSNI and extract genes predicted in more than 60% of the iterations in the
presence of the target as the functional gene set (see code at https://github.
com/caanene1/ACSNI).
Null models
For the evaluation of randomness in the ACSNI predictions, we randomly shuf-
fled the gene expression values of each sample. This process generates
random expression profiles without altering the samples’ library sizes. We
then apply the ACSNI model as described before under the assumption that
the predictions must be false positives, originating from an uninformative
pattern extraction in the W matrix and interaction prediction (P matrix). This
process is included in the ACSNI software and generated automatically.
Datasets for simulation studies
To evaluate how well ACSNI reconstructs a known signal and its FDR, we
created pseudo-simulated RNA-seq data. We did not use purely synthetic
data because we wanted to ensure that our simulation reflects the expected
results from real RNA-seq datasets. Specifically, we extracted the RNA
expression values from the GTEx project (here called expression data) and
50 gene sets from the MSigDB database.18 The expression data have genes
in rows and samples in columns (here called rows and columns, respectively).
The gene sets are sets of gene names (we refer to their expression profiles as
gene set signal). Next, we generated a pair of 50 simulated expression data
and gene set in three independent data transformations:
1. For a given gene set, split the expression data into two groups: (1)
expression of genes in the gene set (data 1) and (2) expression of the
rest of the genes (data 2).
2 .Individually shuffle the column values of data 2, such that the row values
are randomly assigned without altering the original column sums (this is
the random signal).
3. For each row in data 1, individually reverse the ordering of the values
(right to left), whereby the last column gets the expression in the first
column and the first column gets the expression in the last column
(this is the expected signal). This signal is expected because ACSNI
is invariant to the direction and maintains the order of the columns.
4. Create ten versions of data 1 with different log-normal noise levels (5%,
6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, and 50%) randomly added to
each value (this is the set of expected-noise signals). This signal can be
interpreted as the technical noise caused by RNA-seq and alignment
errors. Each of the ten versions has one level of noise and independent
of the other.
5. Finally, for the given gene set merge the transformed datasets from
steps 2 to 5 with data 1 to form one expression matrix (this is the
pseudo-simulated dataset with known signals). Output the row names
of data 1 as the new gene set, creating expression and gene set pairs.
Note that these datasets were analyzed with ASCNI as pairs because each
expected signal is specific to a given gene set.We provide details of the ACSNI
parameters used to analyze the simulated datasets in the results section.Quantification and statistical analysis
Comparison of methods for estimating pathway activity
Other methods are available for estimating sample-wise pathway activity
scores that can be used to infer pathway components comparable with global
ACSNI predictions. To benchmark the global predictions, we compared per-
formance on the validation datasets (genetic perturbations or DNA occupancy
data) with four alternative approaches: GSVA, PLAGE, ssGSEA, and Z
score.12–15 These methods estimate a single activity score for each gene set
and individual sample. In the presented mTOR and ATF2 examples, we used
the version of GSVA, PLAGE, ssGSEA, and Z score implemented in the
GSVAR package to estimate pathway activity for each sample. We then corre-
lated the pathway activities from each method with the expression of each
ll
OPEN ACCESSDescriptorgene across the samples. The gene-wise correlation coefficients were classi-
fied at >0.4 and < 0.4 to predict pathway genes (see code at https://github.
com/caanene1/ACSNI). We did not apply the ACSNI custom classification
method to correlation coefficients because our approach required a beta dis-
tribution, and the correlation coefficients have a different distribution
(Figure S4B).
For the single gene example (HOTAIRM1 annotation using ACSNI-derive
module), we compared the ACSNI prediction with the pairwise correlation
analysis and differential expression analysis between discretized expression
groups (HOTAIRM1-high: >median versus HOTAIRM1-low: <median). For cor-
relation analysis we used the default pearsonr and for differential expression,
ttest_ind implemented in the SciPy Python package. Genes were classified as
pathway components at correlation coefficient of >0.6 and <0.6 or two-tailed
adjusted p values of <0.05 (see code at https://github.com/caanene1/ACSNI).
We estimated the subprocesses activity encoded in the gene set expression
profiles by PCA and NMF dimension reduction to compare ACSNI-step 1 with
linear dimension reduction. We used the default PCA and NMF functions im-
plemented in the sklearn Python package. The optimal number of dimensions
was determined by the number of components required to explain 95% vari-
ation in the expression profiles of the gene set. The loading for each compo-
nent was extracted (i.e., subprocess activity per sample) and used in the
rest of the ACSNI calculations.
For all methods, the input data were either RSEM or transcripts per million
(TPM), which are the preferred data transformations and are also used
in ACSNI.
RNA-seq analysis
For GEO RNA-seq datasets, the raw reads were filtered to remove the adap-
tors and the low-quality reads (Q < 20) using Trimmomatic.39 Filtered reads
were aligned to the human reference genome GRCh38/hg38 assembly using
HISAT2 (v2.1.0) in default settings.40 The counts in different genomic features
were then generated using HTSeq (v0.11.1)41 on human GRCh38 reference
annotation (GENCODE Release 32). The expression levels were normalized
by TPM. Differential expression analyses between two groups were performed
using the limma R package. The DE genes were defined at adjusted p value
of <0.05.
Gene ontology analysis
The R ClusterProfiler and the human Bioconductor annotation database
(org.Hs.eg.db) were used to investigate the biological processes associated
with the predicted components of the studied pathway. Ontologies were
filtered for redundancies by semantic similarity analysis45 and considered sig-
nificant at q value <0.01 or otherwise stated in the figure legends.
Randomization test
We utilized a non-parametric randomization test to evaluate the significance of
the overlap between the genes predicted by ACSNI and genes in a validation
signal, or between two ACSNI predictions. For the comparator variable, we
randomly reassigned the labels and calculated the overlap statistic with the
target labels. We repeated this process 10,000 times and counted the number
of times the overlap statistic was greater than the observed statistic. We
then estimated the empirical probability (empirical p) as the count divided
by the total number of randomizations (i.e., 10,000). The R implementation
of the randomization test analysis is available at https://github.com/
caanene1/ACSNI.
Analysis of probability distribution
The R fitdistrplus and logspline packages were used to investigate the interac-
tion scores’ distribution (Equation 1.6). We computed descriptive parameters
of the score vector and visualized the skewness-kurtosis plot to assess the
possible distribution. We then fitted the set of possible distributions to the
scores and compared their density, quantiles, and probabilities with theoret-
ical values. We selected the best distribution for the data based on the lowest
Akaike information criterion (AIC) across all possible distributions (i.e., we used
distribution with the lowest AIC). The R script for distribution analysis is avail-
able at https://github.com/caanene1/ACSNI.SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.
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